Safety Study of PT-523 in Cancer Patients to Treat Solid Tumors Including a Preliminary Assessment of Effectiveness

Exclusion Criteria

• •Active brain metastases.
• •Presence of third-space fluid collections (pleural effusion, ascites).
• •Major surgery within 3 weeks prior to dosing.
• •Prior chemotherapy or radiation therapy within 3 weeks prior to dosing (6 weeks for nitrosoureas or mitomycin-C). Prior antifolate therapy is permitted, as long as it has not been administered within 3 weeks prior to dosing with PT-523.
• •Prior bone marrow transplantation.
• •Presence of uncontrolled serious medical or psychiatric illness.
• •Patients requiring radiation therapy.